BMEA vs NTRA vs ILMN vs BEAM vs CRSP vs KO

For growth investors, Beam Therapeutics Inc.

(BEAM) is the stronger pick with 120. 0% revenue growth year-over-year, versus -90. 0% for CRISPR Therapeutics AG (CRSP). The Coca-Cola Company (KO) offers the better valuation at 27. 2x trailing P/E (25. 3x forward), making it the more compelling value choice. Analysts rate Biomea Fusion, Inc. (BMEA) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, The Coca-Cola Company (KO) is the cheapest at 27.

2x versus Illumina, Inc. at 29. 5x. On forward P/E, The Coca-Cola Company is actually cheaper at 25. 3x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: The Coca-Cola Company wins at 2. 26x versus Illumina, Inc. 's 7. 29x.

Over the past 5 years, Natera, Inc.

(NTRA) delivered a total return of +104. 4%, compared to -94. 3% for Biomea Fusion, Inc. (BMEA). Over 10 years, the gap is even starker: NTRA returned +1731% versus BMEA's -93. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), The Coca-Cola Company (KO) is the lower-risk stock at -0.

20β versus Beam Therapeutics Inc. 's 2. 18β — meaning BEAM is approximately -1190% more volatile than KO relative to the S&P 500. On balance sheet safety, Biomea Fusion, Inc. (BMEA) carries a lower debt/equity ratio of 5% versus 133% for The Coca-Cola Company — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Beam Therapeutics Inc.

(BEAM) is pulling ahead at 120. 0% versus -90. 0% for CRISPR Therapeutics AG (CRSP). On earnings-per-share growth, the picture is similar: Illumina, Inc. grew EPS 170. 9% year-over-year, compared to -49. 1% for CRISPR Therapeutics AG. Over a 3-year CAGR, CRSP leads at 100. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

The Coca-Cola Company (KO) is the more profitable company, earning 27.

3% net margin versus -165. 7% for CRISPR Therapeutics AG — meaning it keeps 27. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KO leads at 28. 7% versus -161. 9% for CRSP. At the gross margin level — before operating expenses — BEAM leads at 84. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, The Coca-Cola Company (KO) is the more undervalued stock at a PEG of 2. 26x versus Illumina, Inc. 's 7. 29x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, The Coca-Cola Company (KO) trades at 25. 3x forward P/E versus 30. 8x for Illumina, Inc. — 5. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for BMEA: 1626. 5% to $20. 20.

In this comparison, KO (2.

5% yield) pays a dividend. BMEA, NTRA, ILMN, BEAM, CRSP do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, The Coca-Cola Company (KO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.

20), 2. 5% yield, +121. 1% 10Y return). Beam Therapeutics Inc. (BEAM) carries a higher beta of 2. 18 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (KO: +121. 1%, BEAM: +54. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (BMEA (Healthcare) and NTRA (Healthcare) and ILMN (Healthcare) and BEAM (Healthcare) and CRSP (Healthcare) and KO (Consumer Defensive)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: BMEA is a small-cap quality compounder stock; NTRA is a mid-cap high-growth stock; ILMN is a mid-cap quality compounder stock; BEAM is a small-cap high-growth stock; CRSP is a small-cap quality compounder stock; KO is a large-cap quality compounder stock. KO pays a dividend while BMEA, NTRA, ILMN, BEAM, CRSP do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.